Epoetin alfa treatment for patients with chemotherapy-induced anemia

Supportive Cancer Therapy

Volumn 4, Issue 2, 2007, Pages 78-91

  Henry, David H ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

Erythropoietin; Hemoglobin; Quality of life

Indexed keywords

CISPLATIN; HEMOGLOBIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ZIDOVUDINE;

ANEMIA; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; EDEMA; FATIGUE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; NAUSEA; PARESTHESIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOSIS; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 33947141067     PISSN: 15432912     EISSN: None     Source Type: Journal    
DOI: 10.3816/SCT.2007.n.002     Document Type: Review

References (82)

1. American Cancer Society. Cancer Facts and Figures 2006. Atlanta, GA: American Cancer Society; 2006. Available at: http://www.cancer.org/downloads/ STT/CAFF2006PWSecured.pdf. Accessed December 18, 2006.
2. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practice. J Clin Oncol 2003; 21:4524-4531.
3. Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28(2 suppl 8):7-14.
4. Carelle N, Piotto E, Bellanger A, et al. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95:155-163.
5. Tas F, Eralp Y, Basaran M, et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol 2002; 25:371-379.
6. Ludwig H, Van Belle S, Barrett-Lee P. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40:2293-2306.
7. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34(3 suppl 2):13-19.
8. Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000; 37(4 suppl 6):14-17.
9. Curt GA, Johnston PG. Cancer fatigue: the way forward. Oncologist 2003; 8(1 suppl):27-30.
10. Van Belle SJ, Cocquyt V. Impact of hemoglobin levels on the outcome of cancers treated with chemotherapy. Crit Rev Oncol Hematol 2003; 47:1-11.
11. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin Oncol 1994; 21(2 suppl 3):3-8.
12. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91:1616-1634.
13. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990; 322:1689-1992.
14. Bron D, Meuleman N, Mascaux C. Biological basis of anemia. Semin Oncol 2001; 28(2 suppl 8):1-6.
15. National Cancer Institute Common Terminology Criteria for Adverse Events v3.0 (CTCAE); 2006. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf.
16. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001; 91:2214-2221.
17. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. Blood 2002; 100:2303-2320.
18. National Comprehensive Cancer Network. Practice guidelines in oncology. Cancer and treatment-related anemia: v.2.2006. National Comprehensive Cancer Network, Inc., 2006. Available at: http://www.nccn.org/professionals/ physician_gls/PDF/anemia.pdf.
19. Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002; 95:888-895.
20. Gralow JR, Hudis CA, Williams D. Incremental improvements in QOL related to changes in Hb in breast cancer (BC) patients (pts) receiving adjuvant chemotherapy (ADJCT) and QW epoetin alfa therapy. Blood 2003; 102:170b (Abstract #4392).
21. Shasha D, Cremieux P, Harrison L. Relationship between hemoglobin levels and quality of life during radiation therapy plus concomitant or sequential chemotherapy in patients with cancer and anemia treated with epoetin alfa. J Natl Compr Canc Netw 2004; 2:509-517.
22. Procrit [prescribing information]. Raritan, NJ: Ortho Biotech Products, L.P; 2006. Available at: http://www.procrit.com/common/prescribing_information/ PROCRIT/PDF/ProcritBooklet.pdf.
23. Fastenau J, Lefebvre P, Duh MS. Evaluation of the relationship between early hemoglobin rise during epoetin alfa treatment and improved patient-reported quality of life. Proc Am Soc Clin Oncol 2004; 23:756 (Abstract #8124).
24. McKenzie RS, Lefebvre P, Rosberg J, et al. Comparison of anemia outcomes associated with early response to epoetin alfa (EPO) with QW and TIW dosing. Proc Am Soc Clin Oncol 2004; 23:551 (Abstract #6141).
25. Campos SM, Duh MS, Lefebvre, et al. Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia. J Natl Compr Canc Netw 2005; 3:807-816.
26. PRESCRIRE INTERNATIONAL: Epoetin alfa and epoetin beta: treatment of anaemia due to cytotoxic chemotherapy. Prescrire International 2002; 11:39-43.
27. Aranesp [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2006. Available at: http://www.aranesp.com/professional/prescribing_information.jsp.
28. Schwartzberg L, Shiffman R, Tomita D, et al. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia. Clin Ther 2003; 25:2781-2796.
29. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84(1 suppl):3-10.
30. Mulcahy L. The erythropoietin receptor. Semin Oncol 2001; 28(2 suppl 8):19-23.
31. Morreale A, Plowman B, DeLattre M, et al. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004; 20:381-395.
32. Cheung WK, Danneman B, Wacholtz M, et al. Pharmacokinetics and pharmacodynamics of epoetin alfa in anemic cancer patients receiving cycling chemotherapy. Blood 2004; 104:111b (Abstract #4101).
33. Cheung W, Minton N, Gunawardena K. Pharmacokinetics and pharmacodynamics of epoetin alfa once weekly and three times weekly. Eur J Clin Pharmacol 2001; 57:411-418.
34. Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19:2875-2882.
35. Zagari M, Wacholtz M, Xiu L. An open-label, controlled, randomized, dose comparison study of epoetin alfa for the treatment of anemia in cancer patients receiving platinum-based chemotherapy. Poster presented at: 8th European Hematology Association Annual Meeting; June 13, 2003; Lyon, France. (Abstract #0177).
36. Glaspy J, Bukowski R, Steinberg D, et al, for the Procrit Study Group. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol 1997; 15:1218-1234.
37. Demetri GD, Kris M, Wade J, et al. for the Procrit Study Group. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol 1998; 16:3412-3425.
38. Littlewood TJ, Bajetta E, Nortier JW, for the Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19:2865-2874.
39. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin alfa increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer 2003; 98:1072-1079.
40. Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005; 23:2606-2617.
41. Henry DH. Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opin Phamacother 2005; 6:295-310.
42. Henry DH. Anemia in patients with cancer or undergoing cancer therapy: impact and current treatment practice. Transfusion Alternatives in Transfusion Medicine; 2005; 6:14-25.
43. Fallowfield L, Gagnon D, Zagari M, et al. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy. Br J Cancer 2002; 87:1341-1353.
44. Fairclough DL, Gagnon DD, Zagari MJ, et al. Evaluation of quality of life in a clinical trial with nonrandom dropout: the effect of epoetin alfa in anemic cancer patients. Qual Life Res 2003; 12:1013-1027.
45. Jones M, Schenkel B, Just J, et al. Epoetin alfa improves quality of life in patients with cancer: results of a meta-analysis. Cancer 2004; 101:1720-1732.
46. Sloan JA, Schaefer PL, Witzig TE, et al. Relationships among quality of life and survival in anemic patients with advanced cancer undergoing chemotherapy. J Clin Oncol 2005; 23:534s (Abstract #6027).
47. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993; 29A(2 suppl):S2-S8.
48. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2006; 3:CD003407.
49. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-1260.
50. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-5972.
51. Henry DH, Dahl NV. Iron and B12 parameters in anemic cancer patients on chemotherapy presenting for epoetin alfa (EPO) therapy. Proc Am Soc Clin Oncol 2004; 23:747 (Abstract #8091).
52. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86:1528-1536.
53. Patton J, Kuzur M, Liggett W, et al. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy. Oncologist 2004; 9:90-96.
54. Gregory SA, Xie J, Woodman RC. Maintenance dosing with epoetin alfa every two weeks (Q2W) in anemic patients with cancer receiving chemotherapy every one or four weeks: final results. Blood 2005; 106:21b (Abstract #3770).
55. Montoya VP, Xie J, Woodman RC. Maintenance dosing with epoetin alfa every three weeks (Q3W) in anemic patients with cancer receiving chemotherapy every three weeks: final results. Blood 2005; 106:992a (Abstract #3555).
56. Reddy PK, Williams D, Wilhelm FE. An open-label pilot study to evaluate a flexible dosing regimen of epoetin alfa for the treatment of chemotherapy-induced anemia: 60,000 units weekly followed by 60,000 units every 2 weeks. Supportive Cancer Therapy 2006; 4:56-62.
57. Steensma DP, Molina R, Sloan JA, et al. Phase III study of two different dosing schedules of erythropoietin in anemic patients with cancer. J Clin Oncol 2006; 24:1079-1089.
58. Henry DH, Gordan LN, Charu V, et al. Randomized, open-label comparison of epoetin alfa extended dosing (80,000 U Q2W) vs. weekly dosing (40,000 U QW) in patients with chemotherapy-induced anemia. Curr Med Res Opin 2006; 22:1403-1413.
59. Barton JJ, Mody SH, Boudreaux MY, et al. Dosing distribution patterns and associated costs of erythropoietic agents in anemic patients with cancer receiving chemotherapy. Poster presented at: the 40th Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition; December 4-8, 2005; Las Vegas, NV.
60. Harley C, Muser E, Nelson M, et al. Epoetin alfa and darbepoetin alfa utilization patterns among cancer patients. Poster presented at: the 40th Annual American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition, December 4-8, 2005; Las Vegas, NV.
61. Harris HM, del Aguila M, Lopez JM, et al. Anemia treatment costs in cancer patients treated with epoetin alfa or darbepoetin alfa in a managed-care population. J Manag Care Pharm 2005; 11:596.
62. Mark TL, McKenzie RS, Fastenau J, et al. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents. Curr Med Res Opin 2005; 21:1347-1354.
63. Lefebvre P, Gosselin A, McKenzie RS, et al. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations. Curr Med Res Opin 2006; 22:1623-1631.
64. McLaughlin T, Mody SH, McKenzie RS. Real-world dosing of erythropoietic agents in a nationwide sample of patients with cancer receiving chemotherapy: results from a large, retrospective, observational study. Value Health 2006; 9:A111 (Abstract #PCN25).
65. Memisoglu A, Peake C, Buscaino E, et al. Outcomes and costs in epoetin alfa (EPO) and darbepoetin alfa (DARB) treated cancer patients: dosing and outcomes study of erythropoiesis-stimulating therapies (D.O.S.E.) registry. Support Care Cancer 2006; 14:592-593 (Abstract #02-008).
66. Hudis CA, Vogel CL, Gralow JR, et al. Weekly epoetin alfa during adjuvant chemotherapy for breast cancer: effect on hemoglobin levels and quality of life. Clin Breast Cancer 2005; 6:132-142.
67. Crawford J, Robert F, Perry MC, et al. A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small-cell lung cancer scheduled to receive first-line chemotherapy. J Thorac Oncol 2007. In press.
68. Savonije JH, van Groeningen CJ, van Bochove A, et al. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: results of a multicenter, randomized controlled trial. Eur J Cancer 2005; 41:1560-1569.
69. Straus DJ, Testa M, Sarokhan BJ, et al. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer 2006; 107:1909-1917.
70. Moebus V, Kurbacher C, Nitz U, et al. Epoetin alpha prevents anemia and transfusions in patients receiving dose-dense sequential chemotherapy (ETC). Breast Cancer Res Treat 2003; 82(suppl 1):S153 (Abstract #638).
71. Wagner W, Granetzny A, Hilejan L, et al. Hb-level stabilization with epoetin alfa in patients with advanced NSCLC undergoing concurrent neoadjuvant chemo-radiation therapy (phase III study). J Clin Oncol 2006; 24(18 suppl):675s (Abstract #17110).
72. Westphal G, Niederberger E, Blum C, et al. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Tumori 2002; 88:150-159.
73. Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006; 107:1892-1895.
74. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors. Med Oncol 2001; 18:243-260.
75. Glaser CM, Millesi W, Kornek G, et al. Impact of hemoglobin level and use of recombinant human erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001; 50:705-715.
76. Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005; 23:9377-9386.
77. Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from four randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005; 23:6941-6948.
78. Henry DH. The role of intravenous iron in cancer-related anemia. Oncology 2006; 20(8 suppl 6):21-24.
79. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004; 22:1301-1307.
80. Auerbach M, Chaudhry M, Goldman H, et al. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double-blind randomized trial. J Lab Clin Med 1998; 131:257-260.
81. Hedenus M, Birgegard GH, Nasman P, et al. Adjuvant intravenous iron therapy potentiates epoetin beta treatment in anemic, non-iron-depleted patients with lymphoproliferative disorders: results of the NIFE study. Hematol J 2006; 91:365 (Abstract #0996).
82. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Oncologist 2007. In press.